0001628280-24-026140 Sample Contracts
Unaudited Pro Forma Condensed Combined Financial InformationMerger Agreement • June 3rd, 2024 • Avalo Therapeutics, Inc. • Pharmaceutical preparations
On March 27, 2024 (the “Closing Date”), Avalo Therapeutics, Inc. (the “Parent” or “Avalo”) entered into a definitive merger agreement (the “Agreement”) with AlmataBio, Inc., (the “Company” or “Acquiree” or “AlmataBio”) and the Company became a wholly owned subsidiary of the Parent (the “Transaction” or “Merger”).
